Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216895 | 0.83 | AHR (0.35) | MAPTTDP1AHRALDH1A1TSHR | |
| SCHEMBL263819 | 0.75 | MEN1 (0.41) | MAPTLARS1AHRHTR1AMAP3K14 | |
| SCHEMBL31276593 | 0.75 | MAP3K14 (0.33) | LARS1AHRHTR1AMAP3K14 | |
| SCHEMBL13534197 | 0.75 | MAP3K14 (0.42) | LARS1AHRHTR1AALDH1A1KDM4E | |
| SCHEMBL29868877 | 0.75 | PARP1 (0.36) | MAPTLARS1ALDH1A1KDM4EGAA | |
| SCHEMBL4180857 | 0.75 | MAPT (0.42) | MAPTTDP1LARS1AHRALDH1A1 | |
| SCHEMBL419983 | 0.75 | PARP1 (0.36) | MAPTLARS1ALDH1A1KDM4EGAA | |
| SCHEMBL4107808 | 0.73 | PARP1 (0.39) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL30695888 | 0.73 | PARP1 (0.39) | MAPTTDP1ALDH1A1TSHRCYP3A4 | |
| SCHEMBL25166256 | 0.72 | MAPT (0.37) | MAPTTDP1LARS1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-2791121-B1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| EP-2791121-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8524745-B2 | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013090227-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| EP-0982305-B1 | Indane-1-ol derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-03-06 | — | — | EP | disclosed |
| US-6153625-A | Indan-1-ol compounds | ADIR ET COMPAGNIE (FR) | 2000-11-28 | — | — | US | disclosed |
| EP-0982305-A1 | Indane-1-ol derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | MAPT 3955/4885TDP1 1806/4885LARS1 2436/4885 |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR5, CCR2, CX3CR1 | MAPT 4339/4885TDP1 4683/4885LARS1 4637/4885 |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | MAPT 2057/4885TDP1 728/4885LARS1 3260/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | MAPT 1924/4885TDP1 868/4885LARS1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.